What we could do now: molecular pathology of gynaecological cancer.
Gynaecological tumours exemplify many of the molecular paradigms of carcinogenesis. The clinical value of many of the molecular abnormalities present is now being tested and it is likely that the identification of at least some of these will become routine in the near future. This may help to refine diagnosis and guide treatment-for example, therapeutic vaccination for human papillomavirus related disease.
Herrington
C S
CS
Department of Pathology, Duncan Building, Royal Liverpool University of Hospital, Daulby Street, Liverpool L69 3GA, UK. c.s.herrington@liv.ac.uk
D000328:Adult; D004279:DNA, Viral / Q000032:analysis; D004714:Endometrial Hyperplasia / Q000235:genetics / Q000473:pathology; D016889:Endometrial Neoplasms / Q000235:genetics / Q000473:pathology; D005260:Female; D016158:Genes, p53; D005819:Genetic Markers; D005833:Genital Neoplasms, Female / Q000235:genetics* / Q000473:pathology*; D006801:Humans; D008637:Mesenchymoma / Q000235:genetics / Q000473:pathology; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology; D027383:Papillomaviridae / Q000235:genetics; D011237:Predictive Value of Tests; D011379:Prognosis; D012509:Sarcoma / Q000235:genetics / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000235:genetics / Q000473:pathology; D014594:Uterine Neoplasms / Q000235:genetics / Q000473:pathology
D004279:DNA, Viral; D005819:Genetic Markers